The centre on Wednesday decided not to include the affordable Covid antiviral drug Molnupiravir in its National Treatment Protocol due To Some major safety concerns. The decision not to include the antiviral drug was announced by the head of the Indian Council of Medical Research, Balram Bhargava.
Dr. Reddy’s Laboratories Ltd a Hyderabad based pharmaceutical laboratory announced to launch the antiviral drug very soon at a minimal price of Rupees 35 per capsule. The spokesperson of Dr Reddy’s laboratory recently notified that Molflu is the cheapest and affordable treatment o Covid-19 among the adults who are at a higher risk of getting hospitalized due to Covid-19.
Last year, it was notified that Dr. Reddy’s Laboratory agreed to enter into a non-exclusive voluntary licensing agreement with MSD[ Merck Sharpe Dohme] for manufacturing the Covid antiviral drug and supplying it to low and middle-income countries.